Liquet Medical

Overview

Liquet Medical is a pioneering company in the healthcare industry, specializing in the development of medical devices designed for improved treatment of vascular diseases through localized drug delivery. Founded in 2020, Liquet Medical is headquartered in Charlottesville, Virginia. The company was co-founded by John Schindler and Derek Hall, with a vision to revolutionize the treatment of conditions such as pulmonary embolism. The firm has successfully raised approximately $1.8 million to support its innovative projects, particularly the Versus™ Catheter, a breakthrough product in its lineup.

Recent Developments

2024: Liquet Medical was selected to present at the LSI USA '24 conference in Dana Point, California. The presentation focuses on the innovative Versus™ Catheter, emphasizing its role in Hemodynamics-Led Thrombolysis (HLT), a new standard of care for Catheter Directed Thrombolysis.
August 2023: Liquet Medical secured a $368,000 grant from the Virginia Biosciences Health Research Corporation, supporting key milestones like the FDA submission and clearance of the Versus™ Catheter.
April 2023: The company marked its initial success at the RESI (Redefining Early Stage Investments) conference, where it showcased the Versus™ Catheter, gaining significant investor interest.
March 2023: Dr. Gabriele Niederauer was appointed as Chair of the Board of Directors, bringing extensive experience in medical device commercialization from her tenure at Bluegrass Vascular Technologies.
2023: Liquet participated in the Lighthouse Labs RVA, a notable innovation hub, which provided additional exposure and networking opportunities.
2023: Liquet Medical completed pre-clinical in vitro testing and is in the final stages of FDA biocompatibility and verification testing.

Attribute	Information
Founding Date	2020
Headquarters	Charlottesville, Virginia, USA
Founders	John Schindler, Derek Hall
Revenue	Not publicly disclosed
Profits	Not publicly disclosed
Key Investors	Lighthouse Labs, Virginia Catalyst
Industry	Medical Device, Healthcare Technology
Number of Employees	Approximately 10

Early History

Liquet Medical's inception in 2020 was driven by co-founder John Schindler's personal motivation to address vascular diseases, having faced the loss of his mother to pulmonary embolism. The company's foundational technology, the Versus™ Catheter, was developed based on a design by Dr. Patrick Kelly, a practicing vascular surgeon. This catheter aims at improving the treatment of blood clots through a dual-tip system that allows for simultaneous treatment of both lungs. With a strong startup ecosystem in Virginia, the company tapped into resources like the Virginia SBDC to strategize and secure initial funding, facilitating its rapid entry into the competitive medical device market.

Company Profile and Achievements

Liquet Medical operates primarily in the medtech space, focusing on developing novel therapeutic devices for vascular conditions. The Versus™ Catheter, its flagship product, is engineered to enhance patient outcomes through its unique approach to drug delivery and real-time monitoring. Chronologically, the company has achieved several milestones:

2020: Liquet Medical was founded, quickly securing initial seed funding.
2021-2023: The company engaged in extensive R&D activities to refine the Versus™ Catheter, achieving critical pre-clinical validation.
2023: Gained recognition as part of the MedTech Innovator Top 50 startups, highlighting its potential in transforming medical technology.
2024: Progressed towards FDA submission and anticipated completion of first-in-human studies, positioning itself as a frontrunner in personalized vascular treatment technologies.

Current Operations and Market Position

Liquet Medical's primary focus remains the development and commercialization of the Versus™ Catheter. This device is pivotal in addressing pulmonary embolism through precise localized drug delivery. The company operates with a lean but highly proficient team specializing in medical engineering and product development. With several grants and $1.8 million raised through seed funding, Liquet is strategically positioned to expand its market presence. As it approaches FDA clearance, Liquet Medical stands on the cusp of setting new standards in catheter-directed therapies, competing with established medtech giants by offering more innovative, cost-effective solutions.

Conclusion

Liquet Medical is poised to make significant strides in the medical technology industry, particularly in treating vascular diseases. Its innovative Versus™ Catheter represents a major leap in handling pulmonary embolisms, providing real-time data that enhances treatment efficacy and patient care. As Liquet progresses towards FDA approval and clinical adoption, it is set to challenge and transform current treatment paradigms, potentially leading the way towards more personalized, efficient healthcare interventions. The company's growth trajectory suggests a promising future as it continues to align its technological advancements with the evolving needs of the healthcare sector.